Regulus Therapeutics Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
 |
return to message board, top of board |
Re: Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).This is the original reason the anti-miR-17 program was started. It was in the AZ oncology collaboration.It is interesting that it ended up making it to the clinic in kidney disease.
|
||||||||||||||||||
|
|
return to message board, top of board |
